Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Diabetes Technology Driven By Patient Demands

Executive Summary

Integration has become a key driver in the development of a new wave of diabetes tools that have either recently hit the market or will become available in the next few years. Many diabetics, who have a great deal of influence on the success or failure of products in this space, are seeking devices that work seamlessly with the smart phones and cellular technology that are so prevalent today. A number of start-up companies are poised to compete with the bigger diabetes manufacturers as the market continues to evolve.

You may also be interested in...



Digital Health Pushing Telemedicine To Center Stage

Remote monitoring is proving to be the driving force in the industry’s quest to reduce costs by keeping patients out of hospitals, and telemedicine is positioned to become a major part of that scheme. However, telemedicine has a number of components and players, and while the market offers opportunities, it could also prove to be somewhat disruptive to companies and products that do not fit in the envisioned landscape.

Novel Insulin Delivery Systems Pump New Life Into Diabetes Device Market

The market for insulin delivery devices is positioned to change significantly with several manufacturers gearing their products toward type 2 diabetics, who make up 90% to 95% of the diabetes patient pool in the US. These new, “pump-like” devices could offer the type 2 diabetes population better control in managing glucose levels, a solution the medical community has been seeking for a while.

Deals Of The Week Gets Better Connected, Dips A Toe In Digital Health

Digital health promises to transform the quality of health care and reduce costs, but it is not quite yet in a position to help out governments and other payers struggling to meet the demands put on their health care systems. Plus, news of deals between AstraZeneca and Roche, MorphoSys and Celgene, Aspen and Merck, and more.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel